Dr. Gainor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-726-2862- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
- Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
- Harvard Medical SchoolClass of 2008
Certifications & Licensure
- MA State Medical License 2010 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ponatinib in Advanced NSCLC w/ RET Translocations Start of enrollment: 2013 Sep 01
- Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Start of enrollment: 2015 Oct 01
- Pembrolizumab in Refractory Advanced Esophageal Cancer Start of enrollment: 2017 Jan 18
- Join now to see all
Publications & Presentations
PubMed
- Current opportunities and challenges in ALK-positive lung cancer.Lin, J., Gainor, J.> ;Translational Lung Cancer Research. 2024 Jan 31
- Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, Matthew H Taylor, Martin Schuler, Viola W Zhu, Julien Hadoux, Giuseppe Curigliano, Lori Wirth, Justin F Gainor, Guzman Alo...> ;Thyroid. 2024 Jan 1
- Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.Jaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R Digumarthy, Andrew Do, Audrey Liu, Justin F Gainor, Jochen K Lennerz, Timothy F Burns, Jessica...> ;NPJ Precision Oncology. 2023 Nov 3
- Join now to see all
Journal Articles
- Differential Expression of PD-L1 and IDO1 in Association with the Immune Microenvironment in Resected Lung AdenocarcinomasM Lisa Zhang, Justin F Gainor, Meghan J Mooradian, Nature
- Oxford University Press Has Registered This DOI Pre-PublicationR S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
Abstracts/Posters
- A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin LymphomaJustin Gainor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSC...2019 ASCO Annual Meeting - 6/1/2019
- Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. Immunotherapy for Oncogen...2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Press Mentions
- Practical Considerations for Adjuvant vs. Neoadjuvant Immunotherapy in NSCLCJanuary 5th, 2020
- OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerJune 10th, 2019
- Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLCJune 4th, 2019
- Join now to see all
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: